Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10375 in Advanced or Metastatic NSCLC
NCT05435248Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hs-10375 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Mar 2022; status: recruiting.
02
Drugs
hs-10375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05435248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435248.